Dual‐Targeting to Cancer Cells and M2 Macrophages via Biomimetic Delivery of Mannosylated Albumin Nanoparticles for Drug‐Resistant Cancer Therapy

• DOI: 10.1002/adfm.201700403
• Publication Date: 2017-07-10T18:18:40Z
• Authors: Pengfei Zhao; Weimin Yin; Aihua Wu; Yisi Tang; Jinyu Wang; Zhenzhen Pan; Tingting Lin; Meng Zhang; Binfan Chen; Yifei Duan; Yongzhuo Huang
• Keywords: Mannose receptor

Abstract Multidrug resistance (MDR) is an issue that not only related to cancer cells but also associated with the tumor microenvironments. MDR involves complicated cellular events and crosstalk between their surroundings. Ideally, effective system against should take dual action on both The authors find drug‐resistant colon protumor M2 macrophages highly express two nutrient transporters, i.e., secreted protein acidic rich in cysteine (SPARC) mannose receptors (MR). By targeting SPARC MR, a can act macrophages. Herein develop mannosylated albumin nanoparticles coencapsulation of different drugs, disulfiram/copper complex (DSF/Cu) regorafenib (Rego). results show combination therapy DSF/Cu Rego efficiently inhibits growth tumor, has been reported yet for use anticancer treatment. significantly improves treatment outcomes animal model bearing tumors. therapeutic mechanisms involve enhanced apoptosis, upregulation intracellular ROS, anti‐angiogenesis, tumor‐associated macrophage “re‐education.” This strategy characterized by simultaneous macrophages, biomimetic codelivery novel drug combination.